Tilray Brands Inc., through its division Tilray Medical, has announced the publication of a scientific study focusing on the pharmacokinetics of THC and CBD formulations. This research provides insights into the bioavailability of different cannabinoid formulations, contributing to the understanding of medical cannabis for therapeutic treatment. The study involved twelve healthy volunteers and compared the bioavailability of Tilray's THC:CBD extract with nabiximols, revealing higher THC and CBD concentrations with the Tilray extract. No serious adverse events were reported, and the results have already been presented. The findings may have implications for clinical use of these formulations.